Anti-IL-23p19 monoclonal antibody
Mirikizumab
Brand names: Omvoh
Adult dose
Dose: Induction 300mg IV at weeks 0, 4, 8; maintenance 200mg SC every 4 weeks
Route: IV/SC
Frequency: q4w
Clinical pearls
- Moderate-severe ulcerative colitis
- Screen TB / HBV / HCV before starting
Contraindications
- Active severe infection
- Active TB
Side effects
- URTI
- Headache
- Injection site reactions
- Hepatic enzyme rise
- Increased infection risk
Interactions
- Live vaccines
Monitoring
- LFTs
- Infection signs
Reference: BNF; NICE TA928; SmPC; https://bnf.nice.org.uk/drugs/mirikizumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021